Home › Research › Tau biomarkers
Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention
Iqbal K, Grundke-Iqbal I.. Journal of cellular and molecular medicine, 2007-01-09
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer disease (AD) is multi-factorial and heterogeneous. Independent of the aetiology, this disease is characterized clinically by chronic and progressive dementia and histopathologically by neurofibrillary degeneration of abnormally hyperphosphorylated tau seen as intraneuronal neurofibrillary tangles, neuropil threads and dystrophic neurites, and by neuritic (senile) plaques of beta-amyloid. The neurofibrillary degeneration is apparently required for the clinical expression of AD, and in related tauopathies it leads to dementia in the absence of amyloid plaques.
What this study adds
Evidence grade: Low
This is a narrative review. This review discusses the role of neurofibrillary degeneration of abnormally hyperphosphorylated tau in Alzheimer disease and related tauopathies, and considers therapeutic and prevention implications. It is a conceptual review and does not report a tested treatment, cure, or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Iqbal, K., & Grundke-Iqbal, I. (2008). Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. Journal of cellular and molecular medicine. https://doi.org/10.1111/j.1582-4934.2008.00225.x
Vancouver
Iqbal K, Grundke-Iqbal I. Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. Journal of cellular and molecular medicine. 2008. doi:10.1111/j.1582-4934.2008.00225.x. PMID: 18194444.
BibTeX
@article{iqbal2008-18194444,
author = {Iqbal, K. and Grundke-Iqbal, I.},
title = {{Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention}},
journal = {Journal of cellular and molecular medicine},
year = {2008},
doi = {10.1111/j.1582-4934.2008.00225.x},
pmid = {18194444},
url = {https://doi.org/10.1111/j.1582-4934.2008.00225.x}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Independent of the aetiology, this disease is characterized clinically by chronic and progressive dementia and histopathologically by neurofibrillary degeneration of abnormally hyperphosphorylated tau seen as intraneuronal neurofibrillary tangles, neuropil threads and dystrophic neurites, and by neuritic (senile) plaques of beta-amyloid.
- The neurofibrillary degeneration is apparently required for the clinical expression of AD, and in related tauopathies it leads to dementia in the absence of amyloid plaques.
- While normal tau promotes assembly and stabilizes microtubules, the abnormally hyperphosphorylated tau sequesters normal tau, MAP1 and MAP2, and disrupts microtubules.
- The abnormal hyperphosphorylation of tau also promotes its self-assembly into tangles of paired helical and or straight filaments.
Why it matters
This review discusses the role of neurofibrillary degeneration of abnormally hyperphosphorylated tau in Alzheimer disease and related tauopathies, and considers therapeutic and prevention implications. It is a conceptual review and does not report a tested treatment, cure, or prevention.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 46/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 45 of the 97 points we could judge it on, which is 46 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of cellular and molecular medicine) |
| Journal's citation record | 2 / 4 | Journal of Cellular and Molecular Medicine: journal h-index 187 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2008 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 240 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 12.0 citations a year over 20 year(s) since 2008 |
| Impact for its field and year | 4 / 6 | Cited 15.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 3 other studies in this library |
| Still being cited | 2 / 4 | Cited 19 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Inge Grundke‐Iqbal: h-index 103 (OpenAlex, whole career) |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 18194444) |
| Free to read | 2 / 2 | Free to read |
| Points | 45 / 97 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 45 of the 97 points we could judge it on is 46 out of 100. |
| Total | 46 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1111/j.1582-4934.2008.00225.x
- PubMed: 18194444
- Original source →
- Free full text: Journal of Cellular and Molecular Medicine →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 22.
Later studies that cite this one
3 studies in the alzhub library list this one in their references.
Related studies in Tau biomarkers from nearby years
Also in Tau biomarkers
61 studies in the library are filed under Tau biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Tau biomarkers hub.